Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Loading...
Embargo End Date
ICR Authors
Authors
Becherini, C
Visani, L
Caini, S
Bhattacharya, IS
Kirby, AM
Nader Marta, G
Morgan, G
Salvestrini, V
Coles, CE
Cortes, J
Curigliano, G
de Azambuja, E
Harbeck, N
Isacke, CM
Kaidar-Person, O
Marangoni, E
Offersen, B
Rugo, HS
Morandi, A
Lambertini, M
Poortmans, P
Livi, L
Meattini, I
Visani, L
Caini, S
Bhattacharya, IS
Kirby, AM
Nader Marta, G
Morgan, G
Salvestrini, V
Coles, CE
Cortes, J
Curigliano, G
de Azambuja, E
Harbeck, N
Isacke, CM
Kaidar-Person, O
Marangoni, E
Offersen, B
Rugo, HS
Morandi, A
Lambertini, M
Poortmans, P
Livi, L
Meattini, I
Document Type
Journal Article
Date
2023-09-01
Date Accepted
2023-06-10
Abstract
The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving survival outcomes compared to endocrine therapy alone. Abemaciclib and ribociclib, in combination with endocrine therapy, have demonstrated significant benefits in invasive disease-free survival for high-risk HR+/HER2- early breast cancer patients. Each CDK4/6i-palbociclib, ribociclib, and abemaciclib-exhibits distinct toxicity profiles. Radiation therapy (RT) can be delivered with a palliative or ablative intent, particularly using stereotactic body radiation therapy for oligometastatic or oligoprogressive disease. However, pivotal randomized trials lack information on concomitant CDK4/6i and RT, and existing preclinical and clinical data on the potential combined toxicities are limited and conflicting. As part of a broader effort to establish international consensus recommendations for integrating RT and targeted agents in breast cancer treatment, we conducted a systematic review and meta-analysis to evaluate the safety profile of combining CDK4/6i with palliative and ablative RT in both metastatic and early breast cancer settings.
Citation
Cancer Treatment Reviews, 2023, 119 pp. 102586 -
Source Title
Cancer Treatment Reviews
Publisher
ELSEVIER SCI LTD
ISSN
0305-7372
eISSN
1532-1967
1532-1967
1532-1967
Collections
Research Team
Molecular Cell Biology